Other · developed by MapLight Therapeutics
ML-004 is a drug studied in autism spectrum disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05889273 | Phase 2 | Autism Spectrum Disorder | Active not recruiting | MPLT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Autism Spectrum Disorder
Updated Oct 25, 2026. Something wrong or missing? Report it on the MPLT page.
See MPLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MPLT catalysts and pipeline →